Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
statistical analysis
Biotech
Bone breaks from original cell therapy plan, switching endpoint
Bone plans change a primary endpoint and add an interim analysis as part of revisions that will enable it to cut the enrollment target by 20%.
Nick Paul Taylor
Jul 15, 2022 8:25am
Should p-value thresholds be cut to raise data standards?
Mar 23, 2018 10:11am
Biogen tweaks Alzheimer’s phase 3, sparking stock slide
Feb 15, 2018 5:31am
INC Research and Medidata expand partnership on data technology
Mar 3, 2017 4:51pm
